Can oral vancomycin 125 mg every six hours be switched to the liquid formulation at the same dose?

Switching Oral Vancomycin 125mg Q6H to Liquid Formulation

Yes, oral vancomycin 125 mg every 6 hours can be switched to the liquid formulation at the same dose, as both capsule and liquid forms are bioequivalent for treating Clostridioides difficile infection when administered orally. 1

Pharmacokinetic Equivalence

• The FDA label confirms that vancomycin is poorly absorbed after oral administration regardless of formulation (capsule or liquid), with fecal concentrations exceeding 100 mg/kg in the majority of samples during multiple dosing. 1
• Blood concentrations remain undetectable or minimal (<0.76% urinary recovery) with oral administration of either formulation, as the drug acts locally in the gastrointestinal tract. 1
• Both formulations achieve therapeutic fecal concentrations (>3100 mg/kg) necessary for treating CDI. 1

Clinical Guideline Support

• IDSA/SHEA guidelines specify vancomycin 125 mg orally 4 times daily for 10 days as standard treatment for CDI, without distinguishing between capsule and liquid formulations. 2
• The guidelines use the term "by mouth" or "orally," indicating that the route of administration (oral) is what matters, not the specific formulation. 3

Important Practical Considerations

However, prescribing liquid vancomycin at discharge may significantly impact patient outcomes:

• A 2025 retrospective cohort study (n=440) found that patients prescribed vancomycin liquid at discharge had higher readmission rates at 60 days compared to those prescribed capsules (adjusted HR for all-cause readmission 1.87,95% CI 1.19-2.94; CDI-specific readmission HR 2.84,95% CI 1.14-7.06). 4
• The increased readmission risk is attributed to delayed patient access due to lack of availability in community pharmacies and inadequate insurance coverage for compounded liquid formulations. 4
• While no significant difference was observed at 30 days, the 60-day data suggests potential treatment interruptions with liquid formulations. 4

Recommendation for Clinical Practice

For inpatient use, switching between capsule and liquid formulations at 125 mg every 6 hours is clinically appropriate and maintains therapeutic equivalence. 1

For discharge prescriptions, strongly prefer capsule formulations over liquid to avoid access barriers and potential treatment interruptions that may increase readmission risk. 4

• If cost considerations necessitate liquid formulation during hospitalization, ensure the discharge prescription specifies capsules to optimize patient access and adherence. 4
• The dose remains 125 mg orally four times daily regardless of formulation choice. 2, 1